{
    "id": "347c6beb-499f-af61-e063-6394a90a6011",
    "indications": "fludeoxyglucose f 18 injection indicated positron emission tomography ( pet ) imaging following settings :",
    "contraindications": "fludeoxyglucose f 18 injection emits radiation . procedures minimize radiation exposure . calculate final dose end synthesis ( eos ) time using proper radioactive decay factors . assay final dose properly calibrated dose calibrator patient [ description ( 11.2 ) ] .",
    "warningsAndPrecautions": "fludeoxyglucose f 18 injection usp supplied multi-dose , capped glass vial containing 0.74 – 14.8 gbq/ml ( 20 - 400 mci/ml ) , carrier added 2-deoxy-2- [ f 18 ] fluoro-d-glucose , end synthesis , approximately 30 ml . contents vial sterile , clear , colorless , pyrogen-free preservative-free . ndc 81759-001-30 ( 30 ml ) receipt , transfer , handling , possession , product subject radioactive material regulations licensing requirements u.s. nuclear regulatory commission , agreement states licensing states appropriate . store fludeoxyglucose f 18 injection usp vial upright lead shielded container 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59° 86°f ) . store dispose fludeoxyglucose f 18 injection usp accordance regulations general license , equivalent , agreement state licensing state . expiration date time provided container label . fludeoxyglucose f 18 injection usp within 12 hours eos time .",
    "adverseReactions": "none",
    "ingredients": [
        {
            "name": "FLUDEOXYGLUCOSE F-18",
            "code": "0Z5B2CJX4D"
        }
    ],
    "organization": "BAMF Health Inc.",
    "name": "Fludeoxyglucose",
    "effectiveTime": "20250311",
    "indications_original": "Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:",
    "contraindications_original": "Fludeoxyglucose F 18 Injection emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [\n  see Description (11.2)].",
    "warningsAndPrecautions_original": "Fludeoxyglucose F 18 Injection USP is supplied in a multi-dose, capped glass vial containing between 0.74 – 14.8 GBq/mL (20 - 400 mCi/mL), of no carrier added 2-deoxy-2-[F 18] fluoro-D-glucose, at end of synthesis, in approximately 30 mL. The contents of each vial are sterile, clear, colorless, pyrogen-free and preservative-free.\n                  \n                  \n                  NDC 81759-001-30 (30 mL)\n                  \n                  \n                  Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.\n                  \n                  Store the Fludeoxyglucose F 18 Injection USP vial upright in a lead shielded container at 25°C (77°F); excursions permitted to 15°C to 30°C (59° to 86°F).\n                  \n                  \n                  Store and dispose of Fludeoxyglucose F 18 Injection USP in accordance with the regulations and a general license, or its equivalent, of an Agreement State or a Licensing State.\n                  \n                  \n                  The expiration date and time are provided on the container label. Use Fludeoxyglucose F 18 Injection USP within 12 hours from the EOS time.",
    "adverseReactions_original": "None"
}